Lexicon Pharmaceuticals, Inc.

LXRX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009
Operating Activities
Net Income $-82.8M
Depreciation & Amortization $6.2M
Depreciation —
Amortization —
Stock-Based Compensation $5.3M
Net Cash from Operating Activities $-89.0M
Investing Activities
Capital Expenditures $369.0K
Business Acquisitions $0
Net Cash from Investing Activities $11.9M
Financing Activities
Dividends Paid —
Stock Repurchases $88.0K
Net Cash from Financing Activities $91.8M
Net Change in Cash $14.7M
Free Cash Flow $-89.4M
← Newer Page 3 of 3 Older →